NDA 011856 · Pharmacia and Upjohn
Solu-Medrol
Methylprednisolone Sodium Succinate · Injection
Last checked: Nov 20, 2026Latest source record: Nov 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1959
May 18, 1959
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,078
579 Phase 3, 236 recruiting
FAERS reports
46,927
41,904 serious, 8,961 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 27, 2026.
Indications and Usage When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 18, 1959 Original approval · Type 2 - New Active Ingredient
5 products under this application
- SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 125MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 40MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Methylprednisolone" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Steroids In caRdiac Surgery Trial (SIRS Trial)Pivotal-lookingStatus unknown
Population Health Research InstituteAcademic, hospital or other
NCT00427388 · 7,507 participants · Start Jun 2007 · Primary completion Feb 2014
Drug: Methylprednisolone · For: Cardiac Surgical Procedures; Cardiopulmonary Bypass; Systemic Inflammatory Response Syndrome
Sites: Hamilton, Canada
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19Pivotal-lookingStatus unknown
Huashan HospitalAcademic, hospital or other
NCT05855395 · 5,815 participants (planned) · Start May 26, 2023 · Primary completion May 1, 2024
Drug: Glucocorticoid · For: COVID-19
Sites: Fuzhou, China; Quanzhou, China; Guangzhou, China · 15 sites in all
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 TrialPivotal-lookingRecruiting
Thomas EngstromAcademic, hospital or other
NCT07478003 · 5,204 participants (planned) · Start Apr 20, 2026 · Primary completion Apr 20, 2031
Drug: Methylprednisolone 250 mg; NaCl (0,9%) · For: STEMI - ST Elevation Myocardial Infarction
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use8,135
- drug ineffective4,495
- fatigue4,349
- headache4,161
- pain4,119
- infusion related reaction4,031
- nausea3,908
- pyrexia3,843
- dyspnoea3,716
- rash3,258
- arthralgia3,078
- diarrhoea3,046
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 620 |
| 2005 | 732 |
| 2006 | 630 |
| 2007 | 782 |
| 2008 | 777 |
| 2009 | 789 |
| 2010 | 995 |
| 2011 | 1,462 |
| 2012 | 1,369 |
| 2013 | 998 |
| 2014 | 1,379 |
| 2015 | 1,856 |
| 2016 | 1,889 |
| 2017 | 1,907 |
| 2018 | 2,094 |
| 2019 | 3,063 |
| 2020 | 3,755 |
| 2021 | 3,426 |
| 2022 | 4,111 |
| 2023 | 3,747 |
| 2024 | 4,357 |
| 2025 | 3,953 |
| 2026 | 2,231 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Solu-Medrol (Methylprednisolone Sod Succ)
2024 spending
$19K
Beneficiaries
109
227 claims
Per beneficiary
$174
$10.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $58,331 |
| 2021 | $56,062 |
| 2022 | $34,553 |
| 2023 | $30,008 |
| 2024 | $18,937 |
Part D: Solu-Medrol* (Methylprednisolone Sod Succ/PF)
2024 spending
$330K
Beneficiaries
8,497
14,091 claims
Per beneficiary
$39
$8.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $334,958 |
| 2021 | $266,460 |
| 2022 | $235,845 |
| 2023 | $234,841 |
| 2024 | $329,969 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia.
Meduri GU, Shih MC, Bridges L, et al. · Intensive Care Med 2022 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J, Wong MG, Hladunewich MA, et al. · JAMA 2022 · Multicenter Study, Randomized Controlled Trial
- Methylprednisolone for Heart Surgery in Infants - A Randomized, Controlled Trial.
Hill KD, Kannankeril PJ, Jacobs JP, et al. · N Engl J Med 2022 · Randomized Controlled Trial, Multicenter Study
- A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone.
Hong S, Wang H, Li S, et al. · BMC Infect Dis 2023 · Meta-Analysis, Systematic Review
- Methylprednisolone, dexamethasone or hydrocortisone for acute severe pediatric asthma: does it matter?
Doymaz S, Ahmed YE, Francois D, et al. · J Asthma 2022 · Randomized Controlled Trial
- Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.
Jayne DR, Gaskin G, Rasmussen N, et al. · J Am Soc Nephrol 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.